Xilio Therapeutics, Inc. XLO
Set alert
8.03 USD +0.10 +1.26%
At close · Oct 30
8.03 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
7.05 Day range 8.09
7.14 52-week range 11.90
- YTD
- -10.38%
- 1 year
- -28.69%
- Open
- 7.05
- Prev close
- 7.93
- Mkt cap
- 52.84M
- Vol
- 7.91K
- Avg vol
- 12.46K
- EPS
- -0.60
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 7.05
- High
- 8.09
- Forward P/E
- -1.91
- Beta
- -0.20
- Short ratio
- 0.42
- Inst. own
- 29.50%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 1.01
- 200-d avg
- 0.970715
- 1y target
- 4.50
1D chart
Signals (11)
| Name | Time | Ago |
|---|---|---|
| MACD: Sell Signal | 1:37 PM | 2 days ago |
| MACD: Buy Signal | 1:03 PM | 2 days ago |
| SMA: Bearish | 12:44 PM | 2 days ago |
| SMA: Bearish | 12:44 PM | 2 days ago |
| RSI: Oversold | 12:44 PM | 2 days ago |
| MACD: Sell Signal | 12:38 PM | 2 days ago |
| MACD: Buy Signal | 12:28 PM | 2 days ago |
| MACD: Sell Signal | 12:23 PM | 2 days ago |
| MACD: Buy Signal | 12:15 PM | 2 days ago |
| MACD: Sell Signal | 11:45 AM | 2 days ago |
| RSI: Overbought | 11:31 AM | 2 days ago |
Key statistics
- Market cap
- 48.79M
- Enterprise value
- 3.42M
- Trailing P/E
- 0.00
- Forward P/E
- -1.91
- PEG ratio
- 0.00
- Price / sales
- 10.56
- Price / book
- 2.33
- EPS (TTM)
- -1.55
- Beta
- -0.20
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 4.62M
- Revenue growth
- 0.00%
- Free cash flow
- -3.04M
- Total cash
- 61.26M
- Total debt
- 8.41M
- Return on equity
- -170.96%
- Shares outstanding
- 43.96M
- Short % of float
- 0.48%
- 50-day average
- 1.01
- 200-day average
- 0.970715
Analyst view
Consensus: buy
Buy
Price target (mean) 4.50 -44.0% downside
Now 8.03
- Target (low)
- 4.00
- Target (mean)
- 4.50
- Target (high)
- 5.00
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy2
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.24.
Financials — quick view
XLO Revenue — quarterly 18.69M
XLO Net income — quarterly -6.37M
XLO EPS — quarterly -0.33
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.25 | -0.22 | +0.03 | +12.00% |
| Aug 8, 2024 | Jun 1, 2024 | -0.23 | — | — | — |
| Aug 8, 2024 | Jun 1, 2024 | -0.23 | -0.24 | -0.01 | -4.35% |
| May 14, 2024 | Mar 1, 2024 | -0.30 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.30 | -0.59 | -0.29 | -96.67% |
| Apr 1, 2024 | Dec 1, 2023 | -0.62 | -0.64 | -0.02 | -3.23% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 8, 2024 | Raymond James | main | Outperform | Outperform |
| May 30, 2023 | Chardan Capital | reit | Buy | Buy |
| May 11, 2023 | Chardan Capital | reit | — | Buy |
| Jan 27, 2023 | Morgan Stanley | main | — | Overweight |
| Dec 21, 2022 | Chardan Capital | init | — | Buy |
| Nov 10, 2022 | Raymond James | main | — | Outperform |
About Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- xiliotx.com
News
- Xilio Therapeutics Doses First Participant In Its Phase 1/2 Clinical Study Of XTX501 To Treat Metastatic Non-Small Cell Lung Cancer
- Xilio Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of XTX501 in Patients with Metastatic NSCLC
- Raymond James Initiates Coverage On Xilio Therapeutics with Outperform Rating, Announces Price Target of $16
- Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Xilio Therapeutics Appoints Yariv J. Houvras, M.D.
- Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates
- Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
- Cancer Stocks That Are Advancing the Future of Oncology Care
Your note
Sign in to keep a note on XLO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ATLAS VENTURE FUND XI L.P | Beneficial Owner of more than 10% of a Class of Security | Sale | Feb 7, 2024 | 0 |
| GILEAD SCIENCES INC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Dec 17, 2024 | 9,105,450 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 10.39% | 4,566,817 | 5.07M | Sep 29, 2024 |
| Rock Springs Capital Management, LP | 6.83% | 3,003,259 | 3.33M | Sep 29, 2024 |
| Morgan Stanley | 3.46% | 1,522,102 | 1.69M | Sep 29, 2024 |
| Rivervest Venture Management LLC | 3.28% | 1,441,444 | 1.60M | Sep 29, 2024 |
| FMR, LLC | 3.18% | 1,395,853 | 1.55M | Sep 29, 2024 |
| Vanguard Group Inc | 2.05% | 902,531 | 1.00M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.68% | 739,563 | 820.91K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.42% | 182,832 | 202.94K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.36% | 160,024 | 177.63K | Sep 29, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.16% | 71,081 | 78.90K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.15% | 63,994 | 71.03K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.15% | 66,922 | 74.28K | Oct 30, 2024 |